Scarica l'app Stockscreener
8.42
6.13%
-0.55
Dopo l'orario di chiusura:
8.41
-0.010
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.97
Aprire:
$8.97
Volume 24 ore:
4.10M
Relative Volume:
0.91
Capitalizzazione di mercato:
$1.37B
Reddito:
$1.08B
Utile/perdita netta:
$422.82M
Rapporto P/E:
3.693
EPS:
2.28
Flusso di cassa netto:
$-637.33M
1 W Prestazione:
+6.99%
1M Prestazione:
+8.65%
6M Prestazione:
-0.71%
1 anno Prestazione:
+7.54%
Intervallo 1D:
$8.25
$9.19
Intervallo di 1 settimana:
$7.845
$9.276
Portata 52W:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.42 | 1.46B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Why institutional investors increase stakes in Novavax Inc. (NVV1) stockWeekly Market Outlook & Entry and Exit Point Strategies - mfd.ru
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble? - AD HOC NEWS
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035 - Insightace Analytic
Novavax, Inc. (NVAX) Investor Outlook: Exploring a Potential 48.15% Upside in the Biotechnology Arena - DirectorsTalk Interviews
Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX - MarketBeat
(NVAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RSI Check: Is Novavax Inc a defensive stockMarket Rally & Reliable Price Breakout Signals - baoquankhu1.vn
Market Review: Is Novavax Inc a defensive stockProduct Launch & Verified Momentum Stock Watchlist - baoquankhu1.vn
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax rises after a seven-day slide - MSN
Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Novavax (NVAX) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story - Yahoo Finance
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push - simplywall.st
Pfizer Q4 Earnings Preview: Analysts Expect Decline - Intellectia AI
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Earnings Update: Can Novavax Inc stock outperform in a bear marketJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Novavax COVID-19 vaccine approved by the FDA - MSN
Weekly Earnings: Is Novavax Inc a turnaround storyGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
AI Stocks: Whats the beta of Novavax Inc stockPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets - Finviz
Assessing Novavax’s (NVAX) Valuation After Its New Matrix M Licensing Agreement With Pfizer - Sahm
Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
9 High Growth Small Cap Stocks That Are Profitable - Insider Monkey
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx - Yahoo Finance
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - Finviz
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - The Motley Fool
Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline - Finviz
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Why Is Pfizer Stock Rising Tuesday? - Sahm
Has Novavax cracked the code for survival in the vaccine arena? - PharmaVoice
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts - MarketBeat
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Responsive Playbooks and the NVAX Inflection - Stock Traders Daily
Novavax rises after licensing deal with Pfizer - MSN
Novavax, Inc. (NVAX) Stock Analysis: Exploring a 33.84% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant - Sahm
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途牛牛
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novavax Inc Azioni (NVAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Casey Mark J | EVP, Chief Legal Officer |
Dec 11 '25 |
Option Exercise |
0.00 |
41,899 |
0 |
73,972 |
| Draghia-Akli Ruxandra | Section 16 |
Nov 11 '25 |
Option Exercise |
0.00 |
14,257 |
0 |
14,257 |
| MCGLYNN MARGARET G | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,588 |
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):